RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
On 6ix: 6ix.com/news/biocryst-present-new-pediatric-hae-data-american-college-allergy-asthma-immunology
BioCryst Pharmaceuticals, Inc. on 6ix
Story so far
- BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
Earlier from BioCryst Pharmaceuticals
- BioCryst to Report Third Quarter 2025 Financial Results on November 3
- BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
- BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
- BioCryst Announces Departure of Dr. Helen Thackray
- BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
Later from BioCryst Pharmaceuticals
- BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
- BioCryst to Present at Upcoming Investor Conference
- BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
- Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Follow BioCryst Pharmaceuticals into a list and get an email when it puts out news.
Follow BioCryst Pharmaceuticals